285 related articles for article (PubMed ID: 23197890)
1. Human epidermal growth factor receptor-2 in oesophageal cancers: an observational study.
Al-Momani H; Barnes R; El-Hadi A; Shah R; Lewis WG; Edwards P
World J Gastroenterol; 2012 Nov; 18(44):6447-51; discussion p.6450. PubMed ID: 23197890
[TBL] [Abstract][Full Text] [Related]
2. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological characteristics of human epidermal growth factor receptor 2-positive Barrett's adenocarcinoma.
Tanaka T; Fujimura A; Ichimura K; Yanai H; Sato Y; Takata K; Okada H; Kawano S; Tanabe S; Yoshino T
World J Gastroenterol; 2012 Nov; 18(43):6263-8. PubMed ID: 23180947
[TBL] [Abstract][Full Text] [Related]
4. Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment.
Hedner C; Borg D; Nodin B; Karnevi E; Jirström K; Eberhard J
J Clin Pathol; 2018 May; 71(5):451-462. PubMed ID: 29138285
[TBL] [Abstract][Full Text] [Related]
5. HER2 expression in oesophageal carcinoma and Barrett's oesophagus associated adenocarcinoma: An Australian study.
Nagaraja V; Shaw N; Morey AL; Cox MR; Eslick GD
Eur J Surg Oncol; 2016 Jan; 42(1):140-8. PubMed ID: 26422587
[TBL] [Abstract][Full Text] [Related]
6. Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation.
Langer R; Rauser S; Feith M; Nährig JM; Feuchtinger A; Friess H; Höfler H; Walch A
Mod Pathol; 2011 Jul; 24(7):908-16. PubMed ID: 21516080
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of her-2 associated with the progression of esophageal cancer patients.
Wang G; Zhang W; Jiang W; Luan L
Hepatogastroenterology; 2013; 60(128):1972-8. PubMed ID: 24719937
[TBL] [Abstract][Full Text] [Related]
8. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus.
Reichelt U; Duesedau P; Tsourlakis MCh; Quaas A; Link BC; Schurr PG; Kaifi JT; Gros SJ; Yekebas EF; Marx A; Simon R; Izbicki JR; Sauter G
Mod Pathol; 2007 Jan; 20(1):120-9. PubMed ID: 17143264
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis.
Hardwick RH; Barham CP; Ozua P; Newcomb PV; Savage P; Powell R; Rahamin J; Alderson D
Eur J Surg Oncol; 1997 Feb; 23(1):30-5. PubMed ID: 9066744
[TBL] [Abstract][Full Text] [Related]
10. Two updates on oesophagogastric junction adenocarcinoma from the fifth WHO classification: Alteration of definition and emphasis on HER2 test.
Li Y; Li J; Li J
Histol Histopathol; 2021 Mar; 36(3):339-346. PubMed ID: 33377175
[TBL] [Abstract][Full Text] [Related]
11. Chemo-radiotherapy in locally advanced squamous cell oesophageal cancer--are upper third tumours more responsive?
Papp A; Cseke L; Farkas R; Pavlovics G; Horvath G; Varga G; Szigeti A; Bellyei S; Marton S; Poto L; Kalmar K; Vereczkei A; Pozsgai E; Horvath OP
Pathol Oncol Res; 2010 Jun; 16(2):193-200. PubMed ID: 19760123
[TBL] [Abstract][Full Text] [Related]
12. Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma.
König AM; Reeh M; Dancau AM; Rathjens M; Gros S; Uzunoglu FG; Bockhorn M; Simon R; Sauter G; Marx A; Izbicki JR
Anticancer Res; 2013 Nov; 33(11):4975-82. PubMed ID: 24222138
[TBL] [Abstract][Full Text] [Related]
13. EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus.
Birkman EM; Ålgars A; Lintunen M; Ristamäki R; Sundström J; Carpén O
BMC Cancer; 2016 Jul; 16():406. PubMed ID: 27387915
[TBL] [Abstract][Full Text] [Related]
14. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).
Boers JE; Meeuwissen H; Methorst N
Histopathology; 2011 Feb; 58(3):383-94. PubMed ID: 21323962
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry.
Sato-Kuwabara Y; Neves JI; Fregnani JH; Sallum RA; Soares FA
BMC Cancer; 2009 Jan; 9():6. PubMed ID: 19128465
[TBL] [Abstract][Full Text] [Related]
16. Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2).
Feilchenfeldt J; Varga Z; Siano M; Grabsch HI; Held U; Schuknecht B; Trip A; Hamaguchi T; Gut P; Balague O; Khanfir K; Diebold J; Jochum W; Shoji H; Kushima R; Wagner D; Shimada Y; Cats A; Knuth A; Moch H; Aebi S; Hofer S
Br J Cancer; 2015 Sep; 113(5):716-21. PubMed ID: 26313663
[TBL] [Abstract][Full Text] [Related]
17. HER2 status in unusual histological variants of gastric adenocarcinomas.
Giuffrè G; Ieni A; Barresi V; Caruso RA; Tuccari G
J Clin Pathol; 2012 Mar; 65(3):237-41. PubMed ID: 22067088
[TBL] [Abstract][Full Text] [Related]
18. Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma.
Zhan N; Dong WG; Tang YF; Wang ZS; Xiong CL
Med Oncol; 2012 Jun; 29(2):933-40. PubMed ID: 21318736
[TBL] [Abstract][Full Text] [Related]
19. Lymphangiogenesis and prognostic significance of vascular endothelial growth factor C in gastro-oesophageal junction adenocarcinoma.
Xie LX; Zhai TT; Yang LP; Yang E; Zhang XH; Chen JY; Zhang H
Int J Exp Pathol; 2013 Feb; 94(1):39-46. PubMed ID: 23317352
[TBL] [Abstract][Full Text] [Related]
20. Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer.
Kurokawa Y; Matsuura N; Kimura Y; Adachi S; Fujita J; Imamura H; Kobayashi K; Yokoyama Y; Shaker MN; Takiguchi S; Mori M; Doki Y
Gastric Cancer; 2015 Oct; 18(4):691-7. PubMed ID: 25224659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
